FindTrial
Sign In

Thc Effccts of FOXK1 and RUFY3 to EMT and Invasion on Colorcotal Cancer: a Historical and Prospective Cohort Study Based on Tissue Samples.

Thc Effccts of FOXK1 and RUFY3 to EMT and Invasion on Colorcotal Cancer: a Historical and Prospective Cohort Study Based on Tissue Samples.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900027331
Enrollment
Unknown
Registered
2019-11-09
Start date
2019-11-15
Completion date
Unknown
Last updated
2019-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

Case Series:N/A

Sponsors

Nanfang Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with colorectal cancer (including all pathological types of colorectal cancer) diagnosed by the Department of Pathology of Nanfang Hospital and surgically treated in Southern Hospital.

Exclusion criteria

Exclusion criteria: Patients who underwent preoperative chemotherapy.

Design outcomes

Primary

MeasureTime frame
Rufy3 expression level;—

Secondary

MeasureTime frame
FOXK1 expression level;—

Countries

China

Contacts

Public ContactJide Wang

Nanfang Hospital

jidewang55@163.com+86 15217332212

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026